Skip to main content
Clinical Trials/IRCT20190810044500N11
IRCT20190810044500N11
Completed
Phase 3

Topical Timolol Effectiveness for prophylaxy of radiation induced dermatitis in breast cancer patients

Yazd University of Medical Sciences0 sites64 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 3
Status
Completed
Sponsor
Yazd University of Medical Sciences
Enrollment
64

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
Female

Inclusion Criteria

  • Patients older than 18 years with positive histology confirm invasive and localized breast cancer, who are candidates for adjuvant radiotherapy after surgery (breast conserving or mastectomy).
  • Adequate literacy to fill out a consent form, understand the study, use the drug, report pain and possible side effects

Exclusion Criteria

  • Inflammatory or metastatic carcinoma
  • Extensive skin diseases
  • Connective tissue diseases
  • known sensitivity to beta\-antagonist drugs

Investigators

Sponsor
Yazd University of Medical Sciences

Similar Trials